title: [The psychopharmacological treatment of depressive disorders in childhood and adolescence - developments and standards since the «black box» warning].
abstract: Depending on symptom severity, psychopharmacological treatment can be a valuable option in the treatment of depressive disorders in childhood and adolescence. This review provides recommendations for clinical treatment, focusing on suicidality and treatment-resistant patients. The quality of studies regarding the psychopharmacological therapy of depressive disorders in childhood and adolescence has improved since the «black box» warning of the FDA concerning the occurrence of suicidality under treatment with selective serotonin reuptake inhibitors (SSRIs). In Germany, there is proof for a trend toward a more evidence-based psychopharmacological treatment approach within recent years.
authors.affiliation: Klinik für Kinder- und Jugendpsychiatrie und Psychotherapie, Universität Ulm. paul.plener@uniklinik-ulm.de
authors.forename: Paul L
authors.initials: PL
authors.lastname: Plener
authors.forename: Jörg M
authors.initials: JM
authors.lastname: Fegert
authors.forename: Michael G
authors.initials: MG
authors.lastname: Kölch
mesh_terms: D000293:Adolescent; D000928:Antidepressive Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D002648:Child; D003866:Depressive Disorder / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D061218:Depressive Disorder, Treatment-Resistant / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D004348:Drug Labeling; D006801:Humans; D008134:Long-Term Care; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use*; D013405:Suicide / Q000523:psychology; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration; D000092864:Suicide Prevention
chemical_list: D000928:Antidepressive Agents; D017367:Selective Serotonin Reuptake Inhibitors